Review
The FDA warned five companies that are illegally selling food and beverage products with CBD. New York issued 36 adult-use retail licenses and will delay the current 10 medical operators from opening adult-use stores. Canadian sales of cannabis were higher than expected in September but flat with August at C$389.9 million, up 12.2% from a year ago.
I distributed this written material to 420 Investor subscribers during the week:
Here are some of this week's highlights for Focus List names:
Please check the Focus List, (which has technical, fundamental and valuation ratings as well as a market-cap table). To help track market caps, we maintain tables for the Canadian LPs and the American cannabis operators and ancillary companies.
There were comments in over 90 discussions in the Forum. Don't miss out on this most informative part of 420 Investor! Not familiar with the the Forum? This video will help! This is a great way to track your favorite tickers, even those not on the Focus List, and to get your questions answered quickly.
Market Performance
The Global Cannabis Stock Index remained far above its all-time closing low of 11.26 from 9/30. It rose to 13.37 this Friday, ending unchanged during the week. This was a little worse than the 1.5% gain in the S&P 500, which is up 4.0% so far in November. The cannabis index has rallied 1.4% this month-to-date, behind the S&P 500, and it has rallied 18.7% thus far in Q4. This is more than the 12.3% return in the S&P 500.